MedTrace Logo

Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment

NCT04655794 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-12-07

No results posted yet for this study

Summary

The treatment of latent TB with 3HP is an important issue for the prevention of active TB. However, significant proportion of subjects receiving 3HP had adverse reaction. The main purpose of this observation study is to identify subjects who have higher risk to develop adverse reaction. Clinical characteristics and biomarker will be used to predict adverse reaction.

Conditions

  • Adverse Reaction to Drug
  • 3HP

Interventions

DRUG

3HP

all patients taking 3HP under directly observed preventive therapy (DOPT) program

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-19
Primary Completion
2020-11-20
Completion
2021-02-12
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04655794 on ClinicalTrials.gov